Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

ORAL ONCOLOGY is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of oncology with a specific focus on oral diseases and cancers. Since its inception in 1996, this esteemed journal has provided a platform for high-quality research that addresses critical issues in oral surgery, cancer research, and related disciplines. With impressive rankings in Q1 in Oncology and Q1 in Oral Surgery, and recognized as Rank #1 in Dentistry and Oral Surgery by Scopus, ORAL ONCOLOGY consistently publishes impactful articles that contribute significantly to our understanding of oral cancers. The journal is committed to sharing pioneering findings that enhance clinical practices and improve patient outcomes. As a non-open access journal, it provides readers with exclusive access to cutting-edge research, ensuring that professionals, researchers, and students are at the forefront of developments in the field. Situated in the United Kingdom, ORAL ONCOLOGY serves as an indispensable resource for those dedicated to advancing oral health and oncology research through rigorous scientific inquiry and collaboration.

African Journal of Urology (ISSN: 1110-5704, E-ISSN: 1961-9987) is a leading scholarly publication in the field of urology, published by SPRINGER from the United Kingdom. Since adopting an open access model in 2012, this journal has aimed to increase the visibility and dissemination of vital research findings across the African continent and beyond. With a current impact factor and significant standing, as denoted by its Q3 ranking in Urology for 2023, it serves as an essential platform for clinicians, researchers, and students alike. The journal's scope encapsulates all aspects of urology, fostering advancements in both clinical practices and innovative research while specifically addressing healthcare challenges relevant to African populations. As part of its commitment to accessibility and academic excellence, the journal offers full open access to its content, allowing for a broad readership and engagement with cutting-edge studies. Engage with the African Journal of Urology to contribute to and stay informed about vital developments in urological science.

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, is a premier journal dedicated to advancing the fields of hematology and oncology. With its ISSN 0889-8588 and E-ISSN 1558-1977, this esteemed publication has been a cornerstone of clinical scholarship since its inception in 1987, providing comprehensive annual updates that bridge the gap between research and clinical practice. Known for its rigorous editorial standards and impactful contributions, the journal holds a respectable Q2 quartile classification in both hematology and oncology as of 2023, ranking it in the 50th percentile among its peers. Although it is not an open-access journal, the content is accessible to institutions and professionals worldwide. As the scope of the journal expands through 2024, it continues to attract an audience of researchers, healthcare professionals, and students who seek to stay informed on the latest advancements, treatment modalities, and groundbreaking studies in the fields of hematology and oncology.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, published by Wiley, is a leading journal in the field of obstetrics and gynecology that has been disseminating high-quality research since its inception. With an ISSN of 1341-8076 and an E-ISSN of 1447-0756, this journal thrives on contributing to this specialized area of medicine, showcasing innovations and advancements essential for practitioners and scholars alike. Notably, it holds a commendable Impact Factor reflective of its Q2 ranking in both Medicine and Obstetrics and Gynecology categories for 2023, placing it in the 55th percentile among its peers according to Scopus. The journal covers a wide array of topics pertinent to contemporary medical practices and research in Australia and beyond, aiming to foster interdisciplinary dialogue and advance clinical practices. Researchers, professionals, and students will find it an invaluable resource, featuring rigorous peer-reviewed articles that shed light on emerging trends, clinical guidelines, and groundbreaking studies. As it continues to converge on pivotal medical issues up until 2024, JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH stands poised to make a lasting impact in the realm of women's health.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.